Monika U. Serke
Hamm, RP, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations to assess therapeutic responses.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 12, 2026
Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer - Interdisciplinary Guideline of the German Respiratory Society and the German Cancer Society - Abridged Version
Journal: Pneumologie (Stuttgart, Germany)
Published: October 26, 2023
Evolutionary trajectories of small cell lung cancer under therapy.
Journal: Nature
Published: January 25, 2023
Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer": [Annals of Oncology 33 (2022) 57-66].
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 28, 2022
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: June 14, 2021
A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer.
Journal: Therapeutic advances in medical oncology
Published: November 08, 2020
Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of Immunotherapy.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: September 30, 2020
Prognostic markers in resected large cell neuroendocrine carcinoma: a multicentre retrospective analysis.
Journal: Journal of thoracic disease
Published: April 11, 2020
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 31, 2018
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: June 12, 2018
Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab.
Journal: Oncology letters
Published: May 23, 2018
ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIB/IV non-squamous non-small cell lung cancer.
Journal: Medical oncology (Northwood, London, England)
Published: May 16, 2018
Last Updated: 09/26/2026